Novartis AG (NVS)

Market Cap	277.08B +26.9%
Revenue (ttm)	56.58B +6.3%
Net Income	13.53B +5.2%
EPS	6.98 +9.5%
Shares Out	1.91B
PE Ratio	20.47
Forward PE	16.15
Dividend	$3.08 (2.08%)
Ex-Dividend Date	Mar 11, 2026

Volume	539,528
Open	147.80
Previous Close	145.50
Day's Range	147.52 - 148.76
52-Week Range	104.93 - 170.46
Beta	0.52
Analysts	Hold
Price Target	144.00 (-2.77%)
Earnings Date	Apr 28, 2026

About NVS

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Nov 18, 1991
• Employees: 75,267
• Stock Exchange: NYSE
• Ticker Symbol: NVS
• Website: https://www.novartis.com

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Analyst Summary

According to 5 analysts, the average rating for NVS stock is "Hold." The 12-month stock price target is $144.0, which is a decrease of -2.77% from the latest price.

Price Target

$144.0

(-2.77% downside)

Analyst Consensus: Hold